The short version
5 companies supply this market — a reasonable cushion if one runs into trouble.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Dual Action
Acetaminophen, Ibuprofen · ACETAMINOPHEN 250 mg/1; IBUPROFEN 125 mg/1 · Tablet · Oral · Better Living Brands, Llc
NDC 21130-0716-08 · 1 BOTTLE in 1 CARTON / 18 TABLET in 1 BOTTLE · ANDA · View full market →
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
90-day shortage risk (model v2)
0.1%chance of a new FDA shortage posting for acetaminophen and ibuprofen (oral solid) in the next 90 days
price up 19% YoY · sole-source market
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
Is this a "specialty" drug?
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program · Opioid Analgesic REMS Shared System REMS
Regulatory
- Application
- ANDA216994
- TE code
- —
- Approval date
- Jul 10, 2023
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of Acetaminophen, Ibuprofen (Tablet)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Better Living Brands, Llc | ACETAMINOPHEN 250 mg/1; IBUPROFEN 125 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Kai Squared | ACETAMINOPHEN 250 mg/1; IBUPROFEN 125 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Kroger Company | ACETAMINOPHEN 250 mg/1; IBUPROFEN 125 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Target Corporation | IBUPROFEN 125 mg/1; ACETAMINOPHEN 250 mg/1 | Aug 26, 2026 | Sep 2, 2026 |
| Time Cap Laboratories, Inc. | ACETAMINOPHEN 250 mg/1; IBUPROFEN 125 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Target Corporation | IBUPROFEN 250 mg/1; ACETAMINOPHEN 125 mg/1 | Jul 22, 2026 | Aug 19, 2026 |
| Target Corporation | ACETAMINOPHEN 250 mg/1; IBUPROFEN 125 mg/1 | Jul 15, 2026 | Jul 15, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Dual Action — NDC 21130-0716-08," retrieved September 3, 2026, https://drugdashboards.com/drug/21130071608.
Free to cite with attribution — see how the data is put together.